Impact of high-sensitivity next-generation sequencing, measurable residual disease and subsequent stem cell transplant in patients receiving blinatumomab for MRD-positive B-cell acute lymphoblastic leukemia

Key Points

• The main goal is to assess the impact of high-sensitivity next-generation sequencing and stem cell transplant on patients treated with blinatumomab.
• Utilized next-generation sequencing to detect measurable residual disease.
• Evaluated outcomes following stem cell transplant in patients with MRD-positive B-cell ALL.
• Analyzed patient responses to blinatumomab treatment.
• High-sensitivity sequencing effectively identified measurable residual disease.
• Stem cell transplant showed potential to improve patient outcomes.
• Blinatumomab treatment demonstrated efficacy in managing MRD-positive cases.